Direct regulation of fibroblast growth factor 23 by energy intake through mTOR.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 02 2020
04 02 2020
Historique:
received:
10
05
2019
accepted:
20
01
2020
entrez:
6
2
2020
pubmed:
6
2
2020
medline:
18
11
2020
Statut:
epublish
Résumé
To test the hypothesis that fibroblast growth factor 23 (FGF23) is directly regulated by energy intake, in vivo and in vitro experiments were conducted. Three groups of rats were fed diets with high (HC), normal (NC) and low (LC) caloric content that resulted in different energy intake. In vitro, UMR106 cells were incubated in high (HG, 4.5 g/l) or low glucose (LG, 1 g/l) medium. Additional treatments included phosphorus (P), mannitol, rapamycin and everolimus. Intestinal absorption of P and plasma P concentrations were similar in the three groups of rats. As compared with NC, plasma FGF23 concentrations were increased in HC and decreased in the LC group. A significant correlation between energy intake and plasma FGF23 concentrations was observed. In vitro, mRNA FGF23 was significantly higher in UMR106 cells cultured in HG than in LG. When exposed to high P, mRNA FGF23 increased but only when cells were cultured in HG. Cells incubated with HG and mechanistic target of rapamycin (mTOR) inhibitors expressed low mRNA FGF23, similar to the values obtained in LG. In conclusion, this study shows a direct regulation of FGF23 production by energy availability and demonstrates that the mTOR signaling pathway plays a central role in this regulatory system.
Identifiants
pubmed: 32020002
doi: 10.1038/s41598-020-58663-7
pii: 10.1038/s41598-020-58663-7
pmc: PMC7000745
doi:
Substances chimiques
Phosphorus
27YLU75U4W
Fibroblast Growth Factors
62031-54-3
Fibroblast Growth Factor-23
7Q7P4S7RRE
TOR Serine-Threonine Kinases
EC 2.7.11.1
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1795Références
Vervloet, M. Renal and extrarenal effects of fibroblast growth factor 23. Nat. Rev. Nephrol. 15, 109–120 (2019).
doi: 10.1038/s41581-018-0087-2
Shimada, T. et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone. Miner. Res. 19, 429–435 (2004).
doi: 10.1359/JBMR.0301264
Scialla, J. J. et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J. Am. Soc. Nephrol. 25, 349–360 (2014).
doi: 10.1681/ASN.2013050465
Kestenbaum, B. et al. Fibroblast Growth Factor-23 and Cardiovascular Disease in the General Population: the Multi-Ethnic Study of Atherosclerosis. Circ. Hear. Fail. 7, 409–417 (2014).
doi: 10.1161/CIRCHEARTFAILURE.113.000952
Panwar, B. et al. Fibroblast growth factor 23 and risk of incident stroke in community-living adults. Stroke 46, 322–328 (2015).
doi: 10.1161/STROKEAHA.114.007489
Ferrari, S. L., Bonjour, J. P. & Rizzoli, R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 90, 1519–1524 (2005).
doi: 10.1210/jc.2004-1039
Masuyama, R. et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J. Clin. Invest. 116, 3150–3159 (2006).
doi: 10.1172/JCI29463
López, I. et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int. 80, 475–482 (2011).
doi: 10.1038/ki.2011.107
David, V. et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 89, 135–146 (2016).
doi: 10.1038/ki.2015.290
Bozentowicz-Wikarek, M. et al. Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population? Clin. Biochem. 48, 431–436 (2015).
doi: 10.1016/j.clinbiochem.2014.12.027
Marsell, R. et al. Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos. Int. 20, 1167–1173 (2009).
doi: 10.1007/s00198-008-0780-2
di Giuseppe, R. et al. Potential predictors of plasma fibroblast growth factor 23 concentrations: Cross-sectional analysis in the epic-Germany study. PLoS One. 10, e0133580, https://doi.org/10.1371/journal.pone.0133580 (2015).
doi: 10.1371/journal.pone.0133580
pubmed: 26193703
pmcid: 4508099
Bär, L. et al. Insulin suppresses the production of fibroblast growth factor 23 (FGF23). Proc. Natl. Acad. Sci. USA 115, 5804–5809 (2018).
doi: 10.1073/pnas.1800160115
Glosse, P. et al. AMP-activated kinase is a regulator of fibroblast growth factor 23 production. Kidney Int 94, 491–501 (2018).
doi: 10.1016/j.kint.2018.03.006
Raya, A. I. et al. Energy-dense diets increase FGF23, lead to phosphorus retention and promote vascular calcifications in rats. Sci. Rep. 6, 36881 (2016).
doi: 10.1038/srep36881
Rios, R. et al. Phosphorus restriction does not prevent the increase in fibroblast growth factor 23 elicited by high fat diet. PLoS One. 13, e0198481, https://doi.org/10.1371/journal.pone.0198481 (2018).
doi: 10.1371/journal.pone.0198481
pubmed: 29856857
pmcid: 5983526
Poret, J. M. et al. High fat diet consumption differentially affects adipose tissue inflammation and adipocyte size in obesity-prone and obesity-resistant rats. Int. J. Obes. (London). 42, 535–541 (2018).
doi: 10.1038/ijo.2017.280
Wickman, C. & Kramer, H. Obesity and Kidney Disease: Potential Mechanisms. Semin. Nephrol. 33, 14–22 (2013).
doi: 10.1016/j.semnephrol.2012.12.006
Kanbay, M. et al. Novel faces of fibroblast growth factor 23 (FGF23): iron deficiency, inflammation, insulin resistance, left ventricular hypertrophy, proteinuria and acute kidney injury. Calcif. Tissue. Int. 100, 217–228 (2017).
doi: 10.1007/s00223-016-0206-7
de Cavanagh, E. M. V., Inserra, F. & Ferder, L. Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow aging. Coincidences with calorie restriction and mTOR inhibition. Am. J. Physiol. Heart Circ. Physiol. 309, H15–H44 (2015).
doi: 10.1152/ajpheart.00459.2014
Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell. 149, 274–293 (2012).
doi: 10.1016/j.cell.2012.03.017
Tokunaga, C., Yoshino, K. & Yonezawa, K. mTOR integrates amino acid- and energy-sensing pathways. Biochem. Biophys. Res. Commun. 313, 443–446 (2004).
doi: 10.1016/j.bbrc.2003.07.019
Christov, M. et al. Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int. 84, 776–785 (2013).
doi: 10.1038/ki.2013.150
Hanks, L. J., Casazza, K., Judd, S. E., Jenny, N. S. & Gutiérrez, O. M. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One. 10, e0122885, https://doi.org/10.1371/journal.pone.0122885 (2015).
doi: 10.1371/journal.pone.0122885
pubmed: 25811862
pmcid: 4374938
Glosse, P. et al. A high-fat diet stimulates fibroblast growth factor 23 formation in mice through TNFα upregulation. Nutr. Diabetes. 8, 36 (2018).
doi: 10.1038/s41387-018-0037-x
Frommelt, L. et al. Effects of low-carbohydrate, high-fat diets on apparent digestibility of minerals and trace elements in rats. Nutrition. 30, 869–875 (2014).
doi: 10.1016/j.nut.2013.11.017
Kaur, G., Singh, J. & Kumar, J. Vitamin D and cardiovascular disease in chronic kidney disease. Pediatr. Nephrol., https://doi.org/10.1007/s00467-018-4088-y (2018).
doi: 10.1007/s00467-018-4088-y
van Schoor, N. M. et al. Vitamin D deficiency as a risk factor for osteoporotic fractures. Bone. 42, 260–266 (2008).
doi: 10.1016/j.bone.2007.11.002
Botolin, S. & McCabe, L. R. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J. Cell Biochem. 99, 411–424 (2006).
doi: 10.1002/jcb.20842
Xu, J., Ji, J. & Yan, X. H. Cross-Talk between AMPK and mTOR in regulating energy balance. Crit. Rev. Food Sci. Nutr. 52, 373–381 (2012).
doi: 10.1080/10408398.2010.500245
Kempe, D. S. et al. Rapamycin-induced phosphaturia. Nephrol. Dial. Transplant. 25, 2938–2944 (2010).
doi: 10.1093/ndt/gfq172
Peng, H. et al. mTORC1 enhancement of STIM1-mediated store-operated Ca(2+) entry constrains tuberous sclerosis complex-related tumor development. Oncogene. 32, 4702–4711 (2013).
doi: 10.1038/onc.2012.481
Valentine, R. J., Coughlan, K. A., Ruderman, N. B. & Saha, A. K. Insulin inhibits AMPK activity and phosphorylates AMPK Ser485/491 through Akt in hepatocytes, myotubes and incubated rat skeletal muscle. Arch. Biochem. Biophys. 562, 62–69 (2014).
doi: 10.1016/j.abb.2014.08.013
Abdelnour-Berchtold, E. et al. Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin. Anticancer Res. 30, 799–804 (2010).
pubmed: 20392999